Protara Therapeutics (TARA) Stock Price, News & Analysis

Company Overview

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Key Stats

• Today's Range: $3.43 to $3.70
• 50-Day Range: $3.36 to $4.73
• 52-Week Range: $1.60 to $10.48
• Volume: 493,583 shs
• Average Volume: 785,358 shs
• Market Capitalization: $131.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.40
• Consensus Rating: Buy

Protara Therapeutics Stock Analysis - MarketRank™

Protara Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 506th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Protara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Protara Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($3.32) to ($3.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protara Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protara Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protara Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.25% of the float of Protara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Protara Therapeutics has recently decreased by 2.40%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protara Therapeutics does not currently pay a dividend.

Dividend Growth

Protara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.25% of the float of Protara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Protara Therapeutics has recently decreased by 2.40%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.57

News Sentiment

Protara Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Protara Therapeutics this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for TARA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Protara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,145.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Protara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 38.13% of the stock of Protara Therapeutics is held by institutions.

TARA Stock Analysis - Frequently Asked Questions

How have TARA shares performed this year?

Protara Therapeutics' stock was trading at $5.28 at the beginning of 2025. Since then, TARA shares have decreased by 32.2% and is now trading at $3.58.
View the best growth stocks for 2025 here.

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) released its quarterly earnings data on Wednesday, March, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09.

Who are Protara Therapeutics' major shareholders?

Top institutional shareholders of Protara Therapeutics include Oppenheimer & Co. Inc. (0.51%). Insiders that own company stock include Jesse Shefferman, Luke M Beshar, Jacqueline Zummo and Opaleye Management Inc.
View institutional ownership trends.

How do I buy shares of Protara Therapeutics?

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/12/2025
• Today: 5/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TARA
• CIK: 1359931
• Web: www.proteontherapeutics.com
• Phone: (646) 844-0337
• Fax: 781-487-6729
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.40
• High Stock Price Target: $25.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +469.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.96%
• Return on Assets: -49.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.85
• Quick Ratio: 9.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.01 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 36,767,000
• Free Float: 18,051,000
• Market Cap: $131.63 million
• Optionable: Optionable
• Beta: 1.60